THE EFFECTS OF PAROXETINE, ALONE AND IN COMBINATION WITH ALCOHOL ON PSYCHOMOTOR PERFORMANCE AND COGNITIVE FUNCTION IN THE ELDERLY

被引:10
作者
KERR, JS
FAIRWEATHER, DB
MAHENDRAN, R
HINDMARCH, I
机构
[1] HPRU The Robens Institute, University of Surrey, Milford Hospital, Godalming
关键词
ALCOHOL; ELDERLY VOLUNTEERS; LORAZEPAM; MOOD; PAROXETINE; PSYCHOMOTOR PERFORMANCE; SLEEP;
D O I
10.1097/00004850-199211000-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fifteen healthy male volunteers aged over 60 years received acute and repeated doses of paroxetine 20 mg or placebo, and acute doses of lorazepam 1 mg (as a positive internal control) with or without alcohol (0.6 g/kg of body weight) administered openly in a double blind balanced crossover study in which each subject acted as his own control. Psychomotor performance and cognitive function were assessed using a test battery which included critical flicker fusion, choice reaction time, compensatory tracking, Stroop and memory scanning tests. Subjective ratings of mood and sleep were recorded using line analogue rating scales. The pattern of results indicated that paroxetine had little or no effect on most of the test variables, and in some instances (critical flicker fusion thresholds) improved information processing ability. This was in marked contrast to the lorazepam verum which produced sedation and disruption of performance. Paroxetine had a slight antagonistic effect on alcohol induced sedation whereas impairment of performance with lorazepam was potentiated by co-administration of alcohol. The low behavioural toxicity of paroxetine in elderly volunteers has important implications for the pharmacotherapy of depression.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 34 条
[1]   DOUBLE-BLIND COMPARATIVE-STUDY OF PAROXETINE AND AMITRIPTYLINE IN DEPRESSED-PATIENTS OF A UNIVERSITY PSYCHIATRIC OUTPATIENT-CLINIC (PILOT-STUDY) [J].
BATTEGAY, R ;
HAGER, M ;
RAUCHFLEISCH, U .
NEUROPSYCHOBIOLOGY, 1985, 13 (1-2) :31-37
[2]   AN EARLY CLINICAL PHASE-II EVALUATION OF PAROXETINE, A NEW POTENT AND SELECTIVE 5HT-UPTAKE INHIBITOR IN PATIENTS WITH DEPRESSIVE-ILLNESS [J].
BORUP, C ;
MEIDAHL, B ;
PETERSEN, IM ;
VANGTORP, A ;
HONORE, PL .
PHARMACOPSYCHIATRIA, 1982, 15 (06) :183-186
[3]  
BUUSLASSEN A, 1977, ACTA PHARMACOL TOX, V4, P43
[4]  
BUUSLASSEN A, 1978, PSYCHOPHARMACOLOGY, V57, P151
[5]  
FREWER LJ, 1988, PSYCHOPAHRMACOLOGY R
[6]  
HANKS GW, 1984, NOMIFENSINE PHARM CL
[7]  
HINDMARCH I, 1990, J CLIN PSYCHIAT, V51, P34
[8]   CRITICAL FLICKER FUSION FREQUENCY (CFF) - THE EFFECTS OF PSYCHOTROPIC COMPOUNDS [J].
HINDMARCH, I .
PHARMACOPSYCHIATRIA, 1982, 15 :44-48
[9]  
HINDMARCH I, 1991, ALCOHOL ALCOHOLISM, V26, P71
[10]   PSYCHOPHARMACOLOGICAL EFFECTS OF SERTRALINE IN NORMAL, HEALTHY-VOLUNTEERS [J].
HINDMARCH, I ;
BHATTI, JZ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (02) :221-223